Eli Lilly Missed Sales Expectations Again. Should Investors Be Worried?

In the first half of 2024, it seemed Eli Lilly (NYSE: LLY) could do no wrong. Unfortunately, the good times didn't last very long. The stock peaked last October and was down by more than 21% when the market closed on Jan. 16.Is Eli Lilly a good stock to buy on the dip? Here's a look at why it's been beaten down lately to find out.The latest declines in Eli Lilly's stock price occurred in response to management's presentation at the annual JPMorgan Healthcare conference. On Jan. 14, CEO David Ricks told investors that 2024 sales would come in at about $45 billion. That's about 32% more than it reported during the previous year, but less than he told us to expect a few short months ago.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool